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Abstract
Background: Increased circulatory levels of the chemokine CXCL4 have been associated with the presence of
interstitial lung disease (ILD) in an observational study of patients with systemic sclerosis (SSc). The purpose of the
present study was to evaluate the relationship between baseline CXCL4 level and extent of ILD in the context of a
randomized controlled trial and to determine whether changes in CXCL4 levels in response to immunosuppression
are associated with future progression of SSc-ILD.
Methods: A total of 142 SSc-ILD patients from Scleroderma Lung Study (SLS) II were randomized in a double-blind,
parallel-arm trial, to receive mycophenolate (MMF) for 2 years or oral cyclophosphamide (CYC) for 1 year followed
by 1 year of placebo. Plasma CXCL4 levels were measured at baseline, 12 months, and 24 months in SLS II participants
(N = 136) and at a single time point in healthy controls (N = 67). A mixed-effects model evaluated the relationship
between change in CXCL4 levels and SSc-ILD progression. The primary outcome was the course of the forced
vital capacity.
Results: Baseline CXCL4 levels were significantly higher in SSc-ILD patients compared with healthy controls
(2699 ± 1489 ng/ml vs 2233 ± 1351 ng/ml (mean ± SD); P = 0.019). However, no significant correlations were
identified between CXCL4 levels and extent of ILD at baseline, as measured by the forced vital capacity, diffusing
capacity of carbon monoxide, or radiographic extent of ILD. Plasma CXCL4 decreased significantly from baseline to
12 months in all patients (CYC: P < 0.001; MMF: P = 0.006) with no between-treatment differences (CYC vs MMF).
Patients with the largest decline in CXCL4 levels during the first 12 months had an improved course of forced vital
capacity %-predicted from 12 to 24 months (P = 0.040), even after adjusting for baseline disease severity and treatment
arm assignment.
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Conclusions: Levels of CXCL4 were higher in patients with SSc-ILD compared with controls and decreased in all
patients treated with immunosuppressive therapy. While CXCL4 levels were not correlated with extent of ILD at
baseline, changes in CXCL4 at 12 months predicted future progression of SSc-ILD from 12 to 24 months. These
findings suggest that intermediate-term changes in CXCL4 may have predictive significance for long-term
progression of SSc-ILD in patients receiving immunosuppressive therapy.
Trial registration: ClinicalTrials.gov NCT00883129. Registered 16 April 2009.
Keywords: Systemic sclerosis, Pulmonary fibrosis, Chemokines, Immunosuppression
Background
Although interstitial lung disease (ILD) occurs in the ma-
jority of patients with systemic sclerosis (SSc) and is also
the leading cause of death in SSc [1], ILD progression
rates vary considerably in this patient population [2].
Identifying specific factors that may predict response
to immunosuppression is central to improving our
ability to determine which SSc patients may derive the
greatest benefit from ILD-targeted therapy. While nu-
merous studies have examined baseline factors that
are associated with ILD progression [3–9], relatively
few studies have examined whether these factors are
associated with a positive response to immunosup-
pression. In the Scleroderma Lung Study (SLS) I (com-
paring cyclophosphamide (CYC) with placebo), the
severity of reticular infiltrates on baseline high-
resolution computed tomography (HRCT) was associ-
ated with improved responsiveness to CYC therapy
[10]. However, to our knowledge, no studies have ex-
amined responsiveness to therapy with mycophenolate
(MMF) in SSc-ILD.
Biomarkers may have clinical application for predict-
ing response to immunosuppression in patients with
SSc-ILD. Several studies have identified potential circu-
lating biomarkers associated with accelerated SSc-ILD
progression, including interleukin (IL)-6 [11], C-reactive
protein (CRP) [12], monocyte chemoattractant protein-1
(MCP-1) [13], CC chemokine ligand 18 (CCL18) [14,
15], and CXCL4 [16]. However, these markers have
not been consistently shown to predict relevant clin-
ical outcomes across a variety of treatments and SSc
populations. Furthermore, all of the studies assessing
the aforementioned candidate biomarkers were ob-
servational by design and consequently included pa-
tients who exhibited diverse phenotypic expressions
of SSc, received a variety of immunosuppressant
therapies, and were followed for varying periods of
time [11–16].
Of these potential biomarkers, the chemokine, CXCL4,
may play an important role in perpetuating profibrotic ac-
tivity in the SSc-ILD disease state. An observational study
found that CXCL4 levels were higher in SSc patients with
ILD compared with those without ILD in a discovery co-
hort, as well as in two independent replication cohorts
[16]. In a subgroup of patients from this study (N = 79),
SSc patients with high baseline CXCL4 levels had acceler-
ated progression of ILD as measured by a decline in the
diffusing capacity for carbon monoxide (DLCO) [16].
Notably, this study also found that CXCL4 levels were
remarkably higher in SSc patients compared with
healthy controls (270-fold higher) [16].
The present study aimed to evaluate whether the
chemokine CXCL4 is associated with the extent of ILD
in a well-characterized cohort of SSc patients, all of
whom had clinically significant ILD. Unlike previous
studies of this nature, the present study analyzed
CXCL4 at multiple time points in concert with the sim-
ultaneous collection of extensive clinical, physiologic,
and radiographic data. A secondary aim was to deter-
mine whether changes in CXCL4 levels can predict im-
provements in lung function in patients receiving




Participants in the SLS II trial (N = 142) were all adults,
aged 18–75 years, who exhibited either limited or diffuse
cutaneous SSc [17] and active ILD as demonstrated by
restrictive ventilatory impairment (forced vital capacity
(FVC) <80% but ≥45% predicted), exertional dyspnea
(Grade ≥2 on the Magnitude of Task component of the
Mahler Baseline Dyspnea Index (BDI)) [18], and the
presence of any ground glass opacity (GGO; hazy opacity
through which normal lung markings can be discerned)
on HRCT. Key exclusion criteria included pulmonary
hypertension; clinically significant abnormalities on
HRCT not attributable to SSc; and smoking within the
past 6 months or evidence of significant airflow obstruc-
tion. Complete details of the SLS II population have
been reported previously [19].
Healthy control participants were independently re-
cruited at the University of Texas, Houston, and
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matched for age, ethnicity, and gender to SLS II partic-
ipants in a 1:2 ratio.
SLS II study design
Enrolled patients were randomly (1:1 block) assigned in
a double-blind, parallel-arm manner to receive either
oral CYC for 1 year followed by 1 year of placebo or
MMF for 2 years. SLS II was a superiority study con-
ducted at 14 university hospitals throughout the USA
(for the list of sites see Ethics approval and consent to
participate) and recruited patients between November
2009 and January 2013. For complete details of the SLS
II protocol, please see the supplementary Web appendix
accompanying the main SLS manuscript [19]. There
were no significant changes in the protocol involving the
design, outcomes, treatment, or eligibility criteria during
the trial. Baseline measurements included the following
physiological variables: spirometry (FVC and forced ex-
pired volume in 1 second (FEV1)), lung volumes (func-
tional residual capacity (FRC), residual volume (RV), and
total lung capacity (TLC) by whole-body plethysmogra-
phy or helium dilution), hemoglobin-adjusted single-
breath DLCO, and the ratio of DLCO to alveolar volume
(DL/VA). The FVC (primary SLS II endpoint) and
DLCO (secondary SLS II endpoint) were measured every
3 months, and the TLC was measured every 6 months
during the trial. HRCT thoracic imaging was obtained at
baseline and at 24 months and a computer-aided design
(CAD) scoring system was employed to provide quanti-
tative measures of different patterns of ILD as described
previously [19, 20]. The Quantitative ILD (QILD) score
was the sum of all abnormally classified scores, including
scores for quantitative lung fibrosis (QLF, linear reticular
markings), GGO, and honeycomb changes (clustered
air-filled cysts with dense walls). Scores were calculated
as the percentage of voxels for both the whole lung
(WL), including both lungs, and for the lobe of maximal
involvement (LM).
CXCL4 measurement
SLS II plasma samples were collected at the baseline,
12-month, and 24-month study visits and were immedi-
ately processed on-site on the day of collection, stored at
−70 °C, and shipped on dry ice to the central repository
at the University of Texas, Houston. Samples from
healthy controls collected at the University of Texas,
Houston, were handled in the same manner except that
no shipping was required. Validated, commercially avail-
able ELISA kits (Human CXCL4/PF4 Quantikine Kit;
R&D Systems) were used to assess CXCL4 levels. All as-
says were performed in duplicate and the coefficient of
variance was <20%. Technicians performing the assays
were blinded to the study arm assignment. CXCL4 data




Summary statistics were generated for baseline charac-
teristics. A two-sample t test was used to compare con-
tinuous variables and a chi-square test was used to
compare categorical variables. Pearson correlations were
performed to examine the relationship between CXCL4
levels and baseline measures of extent of ILD, as mea-
sured by the FVC, DLCO, QILD, and QLF, as well as the
relationship between baseline CXCL4 levels and platelet
counts.
Relationship between change in CXCL4 and progression
of SSc-ILD
To determine whether a change in plasma CXCL4 might
correlate with or predict the progression of SSc-ILD, we
first plotted the course of measured plasma CXCL4, by
treatment arm, from baseline to 24 months and deter-
mined the corresponding magnitude of change for indi-
vidual subjects from baseline to 12 and 24 months.
Pearson correlations were initially performed to examine
the relationship between the change in CXCL4 levels
from baseline to 12 months and the absolute change for
the primary outcome (FVC %-predicted) and key sec-
ondary outcomes (DLCO %-predicted and HRCT mea-
sures of the extent of ILD).
Following these initial analyses, a mixed-effects model
was generated, the outcome of which was the course of
FVC %-predicted measured in 3-month increments from
12 to 24 months (primary outcome). The model in-
cluded the following covariates: change in CXCL4 from
baseline to 12 months, baseline FVC %-predicted, base-
line extent of quantitative fibrosis/ILD, treatment arm,
and a time trend. The covariate of baseline extent of
quantitative fibrosis/ILD was defined as the first princi-
pal component from a principal component analysis of
the following variables: QILD-LM, QILD-WL, QLF-LM,
and QLF-WL.
All tests were two-sided, and all analyses were per-




At baseline, there were no significant differences in any
of the demographic or key disease-defining characteris-
tics of SLS II participants assigned to MMF vs CYC
(Table 1). Baseline CXCL4 levels (ng/ml) were higher in
SLS II participants (N = 136) compared with healthy
controls (N = 67) (SSc: mean 2699 (SD 1489), median
2480 (IR 1585, 3889); controls: mean 2233 (SD 1351),
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median 1720 (IR 1224, 2874); P = 0.019) (Fig. 1). There
were no significant differences in baseline CXCL4 levels
between treatment arms, between limited or diffuse SSc
patients, between men and women, or between ethnicities
(all P ≥ 0.2). There were also no significant correlations be-
tween baseline CXCL4 and age, or disease duration, as
measured by the onset of the first Raynaud’s phenomenon
symptom (r = −0.10, P = 0.24), or as measured by the onset
of the first non-Raynaud’s phenomenon symptom attribut-
able to SSc (r = 0.040, P = 0.64). Similarly, among the
healthy controls there were no significant differences in
CXCL4 levels between men and women or between eth-
nicities, and nor was there any correlation between
CXCL4 levels and age.
CXCL4 correlations
At baseline there were no significant correlations be-
tween plasma CXCL4 levels and any of the physiologic
or radiographic measures of extent or severity of SSc-
ILD (Table 2). There were also no significant correla-
tions between plasma CXCL4 and extent of SSc-ILD at
12 or 24 months (data not shown).
There was no significant correlation between baseline
CXCL4 and baseline mRSS among all participants (r =
0.10; P = 0.24), or among patients with diffuse cutaneous
sclerosis (N = 80; r = 0.059; P = 0.60).
At baseline, CXCL4 levels demonstrated aweak but signifi-
cant correlationwith the platelet count (r= 0.320,P < 0.001).
Plasma levels of CXCL4 levels decrease in response to
immunosuppression
Among the 136 patients with baseline plasma CXCL4
levels measured, 103 patients had 12-month CXCL4
Table 1 Baseline characteristics of SLS II participants with
CXCL4 measurements at baseline
Cyclophosphamide Mycophenolate
Characteristic N N
Age (years) 71 52.3 ± 9.5 65 52.6 ± 10.0
Female sex (% of patients) 71 77.5 65 69.2
Duration of scleroderma (years) 70 2.5 ± 1.8 63 2.7 ± 1.7
% Limited/% diffuse 71 45.1/54.9 65 36.9/63.1
FVC (%-predicted) 71 66.2 ± 9.9 65 66.6 ± 8.2
FEV1:FVC (%-predicted) 71 83.5 ± 5.6 65 81.8 ± 5.7
TLC (%-predicted) 71 65.4 ± 12.1 65 66.5 ± 10.2
DLCO (%-predicted)a 71 53.8 ± 14.2 65 54.4 ± 11.3
DL/VA (%-predicted) 71 61.0 ± 13.7 65 60.9 ± 11.8
Mahler Dyspnea Index
(focal score)
67 7.0 ± 2.3 61 7.3 ± 2.1
Skin-thickening score (mRSS)b
All patients 71 65
Mean 14.1 ± 10.8 15.2 ± 10.1
Range 2–46 1–41
Patients with dcSSc 39 41
Mean 20.7 ± 9.9 20.7 ± 8.6
Range 3–46 4–41
Patients with lcSSc 32 24
Mean 6.1 ± 4.3 5.9 ± 3.4
Range 2–18 1–14
HAQ disability index (0–3)c 71 0.7 ± 0.7 65 0.7 ± 0.6
QLF-WL 69 9.1 ± 7.0 62 8.2 ± 6.9
QLF-LM 69 23.2 ± 19.2 62 22.5 ± 19.9
QILD-WL 69 32.1 ± 14.2 62 27.2 ± 13.6
QILD-LM 69 53.2 ± 19.3 62 49.8 ± 21.0
Auto-antibody (% positive
in patients tested)
ANA 70 94.3 62 96.8
Topoisomerase-1 70 45.7 62 46.2
RNA polymerase III 70 11.4 62 14.5
Centromere 70 2.9 62 1.6
Th\to 67 7.5 60 5.0
Values are mean ± standard deviation, unless otherwise noted
aAdjusted for hemoglobin
bScores for skin thickening (mRSS) can range from 0 to 51, with higher scores
indicating more severe thickening
cScores for HAQ Disability Index can range from 1 to 3, with higher numbers
indicating greater disability
FVC forced vital capacity, FEV1 forced expired volume in 1 second, TLC total
lung capacity, DLCO diffusing capacity of the lung for carbon monoxide, DL/VA
ratio of DLCO to alveolar volume, mRSS modified Rodnan skin score, dcScc
diffuse cutaneous systemic sclerosis, lcSSc limited or cutaneous systemic
sclerosis, HAQ Health Assessment Questionnaire, QLF quantitative extent of
lung fibrosis on high-resolution chest computed tomography, QILD quantita-
tive extent of total interstitial lung disease (including fibrosis, honeycomb, and
ground glass opacity), WL whole lung, LM lobe of maximal involvement
ANA Anti-nuclear antibody, Th/To Th/To ribonucleoprotein antibody
Fig. 1 Plasma CXCL4 levels (ng/ml) were significantly higher in SSc-ILD
patients (N = 136) compared with healthy controls matched for age,
gender, and ethnicity (N = 67), P = 0.019. SSc systemic sclerosis
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measurements (CYC = 50; MMF = 53), and 86 patients
had 24-month CXCL4 measurements (CYC = 41;
MMF = 45) (Fig. 2). CXCL4 levels were measured in
all patients who returned for the follow-up study visits
at 12 and 24 months.
The majority of patients in both treatment arms expe-
rienced a decrease in CXCL4 levels from baseline to
12 months (CYC: 76% (37/49); MMF: 67% (35/52)) and
from baseline to 24 months (CYC: 70% (28/40); MMF:
68% (30/44)). Plasma CXCL4 levels declined significantly
in the CYC and MMF arms (P < 0.001 and P = 0.006, re-
spectively). Similarly, CXCL4 levels showed a significant
decrease from baseline to 24 months in the CYC and
MMF arms (P < 0.001 and P = 0.011, respectively).
Although participants in the CYC arm experienced nu-
merically larger decreases in CXCL4 levels, there was no
statistically significant difference in the change in
CXCL4 levels between treatment arms from baseline to
12 months (P = 0.120) or from baseline to 24 months
(P = 0.380) (Fig. 3). While CXCL4 levels slightly in-
creased from 12 to 24 months in the CYC arm (during
the placebo phase), CXCL4 levels continued to decline
from 12 to 24 months in the MMF arm.
Changes in plasma levels of CXCL4 levels may predict
improved course of FVC
As reported previously [19], the course of the FVC in
SLS II improved significantly from baseline to 24 months
in both the CYC and MMF treatment arms, with no
between-treatment difference. Of note, FVC measure-
ments were obtained in 51 and 59 participants at
12 months and in 50 and 53 participants at 24 months
for the CYC and MMF arms, respectively. When
changes in the plasma CXCL4 levels at 12 months were
correlated with changes in the FVC (bivariate analysis),
there was a trend for a negative correlation between the
change in CXCL4 from baseline to 12 months and the
change in FVC from baseline to 18 months (r = −0.203;
P = 0.063), 21 months (r = −0.212; P = 0.062), and
24 months (r = −0.182; P = 0.082), but not at 12 months
(r= −0.070; P = 0.499) or 15 months (r= −0.048; P = 0.662).
There were no significant correlations between the
change from baseline in CXCL4 at 12 months and the
change from baseline in DLCO at 12, 15, 18, 21, or
24 months (all P > 0.3). There was also no significant
correlation between the change from baseline in CXCL4
at 12 months and the change from baseline in QLF-LM/
WL or QILD-LM/WL at 24 months (all P > 0.4).
Table 2 Baseline CXCL4 levels are not correlated with extent of
ILD in SLS II subjects
Surrogate ILD measurements Pearson correlation (r) P value
TLC% predicted 0.123 0.154
FVC% predicted 0.089 0.304





Values are mean ± standard deviation, unless otherwise noted
ILD interstitial lung disease, SLS Scleroderma Lung Study, FVC forced vital
capacity, TLC total lung capacity, DLCO diffusing capacity of the lung for
carbon monoxide, QLF quantitative extent of lung fibrosis on high-resolution
chest computed tomography, QILD quantitative extent of total interstitial lung
disease (including fibrosis, honeycomb, and ground glass opacity), WL whole
lung, LM lobe of maximal involvement
Fig. 2 Disposition of SLS II study participants with regard to CXCL4 measurement during the 24-month trial. FVC measurements were obtained in
51 and 59 participants at 12 months and in 50 and 53 participants at 24 months for the CYC and MMF arms, respectively. CYC cyclophosphamide,
MMF mycophenolate, SLS Scleroderma Lung Study
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To further explore the relationship between the
change in CXCL4 and the course of the FVC, a mixed-
effects model was generated and the results demon-
strated that the change in CXCL4 from baseline to
12 months was associated with the course of the FVC
(as a continuous variable) from 12 to 24 months (esti-
mate −1.232; 95% CI −2.405, −0.060; P = 0.040), after
controlling for treatment arm assignment, a time trend,
baseline quantitative extent of ILD/fibrosis, and baseline
FVC. A similar statistical approach was used in the ana-
lysis of the primary and secondary outcomes in SLS II
[19]. The results demonstrated that every 1-unit de-
crease in the log CXCL4 level was associated with a
1.23% increase in the FVC. In other words, patients who
experienced the greatest decline in CXCL4 levels during
the first 12 months of the study had an improved course
of FVC from 12 to 24 months (Table 3).
Given the significant correlation between CXCL4
levels and platelet count at baseline, baseline platelet
count was added to the mixed-effects model. Adding
baseline platelet count to the model did not affect the
significant relationship between change in CXCL4 levels
and the outcome variable. However, the baseline platelet
count was not independently associated with the course
of the FVC (P = 0.163), and for this reason this variable
was not included in the final model.
Because not all patients had CXCL4 measurements at
12 months, the final model included 97 patients with
SSc-ILD. Notably, there were no significant differences
in baseline characteristics (i.e., age, gender, diffuse/lim-
ited, FVC, DLCO, MRSS, QILD-WL/LM, QLF-WL/LM)
between the 97 patients included in the final mixed-
effects model and the 39 patients who were not
included.
Discussion
In a well-characterized cohort of patients with SSc-ILD,
CXCL4 levels decreased significantly in response to im-
munosuppressive therapy with both CYC and MMF.
Furthermore, a greater change in CXCL4 from baseline
to 12 months led to improvements in SSc-ILD at
24 months as measured by the FVC %-predicted. These
findings suggest that intermediate-term changes in
CXCL4 may have predictive significance for long-term
progression of SSc-ILD in patients receiving immuno-
suppressive therapy.
These findings are consistent with the purported
pathobiological role of CXCL4 in moderating fibrotic
and inflammatory processes. In addition to the previ-
ously reported association with various dimensions of
SSc [16], CXCL4 levels have also been elevated in liver
fibrosis [21] and in patients with antiphospholipid syn-
drome [22]. In a recent study, CXCL4 blocked the
induction of the anti-inflammatory enzyme heme
oxygenase-1. Furthermore, the product of heme oxy-
genase enzymatic activity, bilirubin, showed an inverse
correlation with CXCL4 levels in plasma samples of
SSc patients [23]. While our understanding of the role
of CXCL4 in the development of SSc-ILD is evolving,
the present manuscript provides further support for its
role in the pathogenesis of SSc.
This study further sheds light on plausible biological
mediators/targets of the two immunosuppressant agents
under study (i.e. MMF and CYC). Although CXCL4
levels were not correlated with any of the baseline surro-
gate markers of ILD severity, CXCL4 levels significantly
declined in both treatment arms in response to im-
munosuppression. Furthermore, the decline in CXCL4
paralleled the improvements appreciated in the course
Fig. 3 CXCL4 levels decreased significantly in response to
immunosuppression in each treatment arm from baseline to
12 months (CYC: P < 0.001; MMF: P = 0.006) and from baseline
to 24 months (CYC: P< 0.001; MMF: P= 0.011). There was no between-
treatment difference in the reduction in CXCL4 from baseline to
12 months or from baseline to 24 months. CYC cyclophosphamide,
MMF mycophenolate
Table 3 Multivariable analysis examining the relationship
between change in CXCL4 from baseline to 12 months and the
course of FVC from 12 to 24 months (N = 97)
Baseline covariate Estimate 95% CI P value
ΔCXCL4 −1.232 −2.405, −0.060 0.040
Baseline FVC 0.972 0.807, 1.138 <0.0001
Baseline QILD/QLFa 0.297 −0.496, 1.089 0.464
Treatment arm −0.361 −3.182, 2.460 0.802
aDefined as the first principal component from a principal component analysis
of the following variables: QILD-LM, QILD-WL, QLF-LM, and QLF-WL
FVC forced vital capacity, CI confidence interval, QLF quantitative extent of
lung fibrosis on high-resolution chest computed tomography, QILD quantitative
extent of total interstitial lung disease (including fibrosis, honeycomb, and ground
glass opacity),WL whole lung, LM lobe of maximal involvement
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of the FVC over 24 months as reported in the main SLS
II manuscript [19]. Although there was no significant
difference in the degree to which CXCL4 decreased be-
tween treatment arms, the sample size may have limited
our ability to detect a difference because CXCL4 levels
appeared to decrease to a greater extent in the CYC arm
compared with the MMF arm within the first 12 months
of treatment (Fig. 3). Interestingly, CXCL4 levels de-
clined most dramatically during the first 12 months of
therapy in both study arms. The patients assigned to
CYC received placebo in the second year, which may ex-
plain the slight upward trend in CXCL4 levels during
the second year of the study. However, the CXCL4 levels
did not return to those observed at the baseline visit
after 2 years in the CYC arm. This finding may in part
be related to the use of alternate therapy during the lat-
ter period. Of the 15 subjects in SLS II who withdrew
from or failed treatment but returned for final study out-
come measures, 12 indicated that they were switched to
potentially disease-modifying therapy (MMF, intravenous
CYC, rituximab, tocilizumab, intravenous immunoglobu-
lin, or azathioprine) and these alternative therapies may
have influenced the results [19]. In the MMF arm,
CXCL4 levels continued to decline during the second
year of the study, likely related to continuous use of im-
munosuppression in this arm.
Interestingly, we did not observe significant correla-
tions between baseline CXCL4 levels and extent of ILD
as measured by the FVC, DLCO, TLC, or extent of
quantitative radiographic fibrosis at baseline, 12 months,
or 24 months. While a prior study [16] demonstrated
that patients with high CXCL4 were more likely to have
fibrosis on HRCT, this prior observational study in-
cluded SSc patients both with and without ILD and at
varying disease stages. By contrast, the present study
only included patients with ILD at a relatively early stage
of disease (mean disease duration of 2.6 years from the
onset of the first non-Raynaud’s symptom attributable to
SSc), nearly all of whom already had evidence of fibrosis
on HRCT [19]. Our findings suggest that CXCL4 may
be a more useful predictive biomarker for response to
immunosuppression in patients with early SSc-ILD.
Whether CXCL4 correlates with severity of ILD at later
stages of SSc remains uncertain. Furthermore, because
our cohort did not evaluate SSc patients without ILD,
we could not assess whether CXCL4 levels can distin-
guish SSc patients with and without ILD.
We did observe a significant but weak correlation be-
tween CXCL4 levels and platelet levels. However, the
platelet level did not demonstrate predictive significance
for FVC progression in the mixed-effects model. Import-
antly, precautions were taken to limit platelet activation,
which can significantly affect CXCL4 levels, including
using strict caution to minimize venostasis during the
blood draw with butterfly needles and immediately cen-
trifuging the specimens. Of note, the prior study in this
area [16] did not assess platelet levels.
Consistent with the work of van Bon et al. [16], we ob-
served an increase in plasma CXCL4 levels in SSc-ILD
patients compared with healthy controls. However, the
magnitude of this difference was strikingly smaller in the
present study (1.6-fold increase in our study vs 277-fold
increase in the previous study). The observed difference
in CXCL4 levels between SSc-ILD patients and healthy
controls in the present report is consistent with the re-
ported fold increases of other cytokines and chemokines
in SSc plasma samples [12, 24]. While several possible
explanations for this disparity exist, we note that we
used a different ELISA assay in the present study than in
the previous study (R&D Systems/Quantikine in the
present study vs R&D Systems/DuoSet in the previous
study). The assay we utilized has been fully validated for
the measurement of CXCL4 in complex fluids such as
serum and plasma [25].
There are notable strengths of the present study. First,
this is the first study to measure CXCL4 levels at mul-
tiple time points in patients with early, symptomatic
SSc-ILD. Second, our initial measurement of CXCL4 oc-
curred prior to the initiation of immunosuppressive
therapy for SSc-ILD; thus, the reported baseline levels of
CXCL4 are likely closely related to the underlying dis-
ease state without any interference from disease-
modifying therapies (patients were ineligible for SLS II if
they had received CYC or MMF for >8 weeks ever in the
past, or they had received intravenous CYC more than
twice ever in the past, or were taking CYC/MMF/any
medication with potential disease-modifying activity
within 30 days of randomization). Third, unlike prior ob-
servational studies in this field, this cohort had uniform
follow-up measurements with likely less missing data.
Fourth, our analyses controlled for treatment assign-
ment. Finally, this study was conducted at 14 centers
and included patients from varying ethnic backgrounds,
thereby increasing the generalizability of our findings.
The results of the present study should be interpreted
within the context of certain limitations. Namely, al-
though we attempted to control for treatment group,
some patients in the SLS II cohort initiated alternate
therapy for SSc-ILD during the course of the trial. Given
the relatively small number of patients who switched
therapies and the observation that there was no differ-
ence in the change in CXCL4 between the two treatment
groups, it is unlikely that the use of alternate therapies
would alter the outcomes of the present analyses. An-
other shortcoming was that only patients who returned
for a 12-month and 24-month visit provided blood sam-
ples. The missing CXCL4 data reduce the statistical
power of the analysis and may yield biased estimates.
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Future studies may consider measuring CXCL4 at even
earlier time points as a means of determining treatment
response prior to 1 year. While we report that the
change in CXCL4 at 1 year was associated with im-
proved SSc-ILD progression at 2 years, additional studies
would be useful to determine whether changes in
CXCL4 at earlier time points might have similar predict-
ive value. If the latter were found, it might be useful
from a clinical standpoint to determine whether a pa-
tient is responding to a particular therapy at 3 or
6 months, to avoid the unfruitful continuation of an in-
effective therapy.
Conclusions
While CXCL4 was not associated with extent of SSc-ILD at
baseline, this chemokine decreased significantly in response
to immunosuppressive therapy. Moreover, the change in
CXCL4 levels was associated with future progression of
SSc-ILD. Although the exact role of CXCL4 in the pathobi-
ology of SSc-ILD is uncertain, these findings support the
potential predictive capability of this chemokine for deter-
mining response to immunosuppressive therapy.
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